Wei Xu
Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Peking Union Medical College Hospital(CN)Zhejiang University(CN)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, Immunodeficiency and Autoimmune Disorders, Acute Myeloid Leukemia Research
Most-Cited Works
- → Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study(2012)383 cited
- → The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic(2018)301 cited
- → Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase(2020)179 cited
- → Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies(2015)168 cited
- → Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma(2011)163 cited
- → Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study